Beclomethasone (QVAR)

Beclomethasone, commonly available as QVAR, is an inhaled corticosteroid medication used in feline medicine for the long-term management of asthma and other inflammatory airway diseases. This medication represents a significant advancement in feline respiratory care, allowing targeted delivery of anti-inflammatory medication directly to the airways while minimizing systemic absorption and associated side effects. Inhaled corticosteroids have become a cornerstone of modern feline asthma management, providing effective control of airway inflammation through a convenient delivery system that many cats can learn to accept with proper training and patience.

The mechanism of action of beclomethasone involves suppression of the inflammatory processes that underlie feline asthma and related conditions. When inhaled, the medication deposits directly on the airway surfaces where it inhibits the production and release of inflammatory mediators, reduces swelling and edema of the airway lining, decreases mucus production, and prevents the recruitment of inflammatory cells to the airways. These effects address the fundamental pathology of asthma rather than simply relieving symptoms. Over time, consistent use of inhaled beclomethasone can reduce airway hyperreactivity and decrease the frequency and severity of asthma attacks. The anti-inflammatory benefits typically become apparent over days to weeks of regular use rather than providing immediate relief.

Beclomethasone is administered to cats using a metered-dose inhaler attached to a specially designed feline aerosol chamber, such as the AeroKat. The chamber includes a face mask that fits over the cat's nose and mouth, allowing the medication to be breathed in over several respiratory cycles. This delivery system overcomes the challenge that cats cannot coordinate inhalation with inhaler actuation as humans do. The chamber holds the medication as an aerosol cloud, giving the cat time to inhale the particles during normal breathing. While training a cat to accept the chamber and mask requires patience, most cats can be successfully conditioned to tolerate the process, making inhaled therapy practical for long-term management.

The safety profile of inhaled beclomethasone is substantially better than systemic corticosteroids because the medication acts locally in the airways with minimal absorption into the bloodstream. This targeted delivery allows for effective control of airway inflammation without the significant side effects associated with oral or injectable steroids, such as increased thirst and urination, diabetes risk, and immune suppression. However, inhaled corticosteroids are not without potential effects, and appropriate veterinary supervision is important throughout therapy. Regular follow-up allows assessment of treatment response, evaluation for any adverse effects, and adjustment of the treatment plan as needed to achieve optimal asthma control.

The primary indication for beclomethasone in cats is the long-term management of feline asthma, a chronic inflammatory condition affecting the lower airways. Feline asthma is one of the most common respiratory diseases in cats, characterized by eosinophilic airway inflammation, bronchospasm, excessive mucus production, and airway remodeling over time. The condition manifests clinically with symptoms including coughing, wheezing, labored breathing, and in severe cases, respiratory distress. Beclomethasone addresses the inflammatory foundation of asthma, reducing airway swelling and reactivity to prevent symptoms rather than simply treating them after they occur. This preventive approach makes inhaled corticosteroids the foundation of asthma maintenance therapy for many cats.

As a maintenance medication, beclomethasone is used regularly to prevent asthma symptoms rather than to treat acute attacks. Cats with asthma typically receive inhaled beclomethasone once or twice daily on an ongoing basis, regardless of whether they are currently experiencing symptoms. This consistent anti-inflammatory therapy gradually reduces airway inflammation and hyperreactivity, resulting in fewer and less severe asthma episodes over time. The medication does not provide immediate relief during acute bronchospasm, so cats with significant asthma typically also have access to rescue bronchodilator medications for breakthrough symptoms. The goal of maintenance therapy is to minimize the need for rescue medication use.

Chronic bronchitis in cats can also benefit from inhaled beclomethasone therapy. While chronic bronchitis has different underlying causes than allergic asthma, airway inflammation is a key component of both conditions. The anti-inflammatory effects of beclomethasone help reduce bronchial inflammation, decrease mucus production, and improve overall airway function in cats with chronic bronchitis. Treatment protocols for bronchitis may differ somewhat from asthma management, and veterinarians develop individualized plans based on the specific diagnosis and disease severity. Inhaled corticosteroid therapy may be combined with other treatments such as bronchodilators or systemic medications depending on the cat's response.

Beclomethasone may be used in various other situations involving feline airway inflammation. Eosinophilic bronchopneumopathy, a condition characterized by eosinophilic infiltration of the lungs and airways, often responds to corticosteroid therapy, and inhaled delivery can provide benefits while minimizing systemic effects. Cats transitioning from systemic corticosteroids may use inhaled beclomethasone as their oral steroid doses are gradually reduced, eventually maintaining adequate control with inhaled therapy alone. This transition can significantly reduce long-term side effects in cats previously dependent on oral prednisolone. The specific approach depends on disease severity and individual patient factors.

The selection of beclomethasone among available inhaled corticosteroids depends on several factors. QVAR beclomethasone uses a hydrofluoroalkane propellant that produces smaller medication particles compared to older inhaler formulations, potentially improving deposition in small airways. The specific potency and dosing characteristics of beclomethasone make it appropriate for many cats, though other inhaled corticosteroids such as fluticasone are more commonly prescribed in feline practice due to greater veterinary experience with these products. Veterinarians may choose beclomethasone based on availability, cost considerations, or individual patient response to different inhaled steroids.

Dosing of inhaled beclomethasone for cats is determined by the veterinarian based on the severity of respiratory disease, the size of the patient, and response to therapy. Inhaled medications are typically dosed by the number of actuations from the metered-dose inhaler rather than by traditional weight-based calculations, though the veterinarian considers the cat's size when determining appropriate therapy. The medication is administered using a feline-specific aerosol chamber with an attached face mask, and the veterinarian provides specific instructions regarding the number of puffs and frequency of administration. Starting doses may be adjusted based on clinical response over the initial weeks of therapy.

The technique for administering inhaled beclomethasone to cats requires training both the cat and the owner. The metered-dose inhaler is attached to the aerosol chamber, and after shaking the inhaler, one actuation is delivered into the chamber. The face mask is then gently but firmly placed over the cat's nose and mouth, creating a seal. The cat breathes normally through the mask for approximately seven to ten breaths, allowing the medication particles to be inhaled from the chamber. If multiple puffs are prescribed per treatment, the process is repeated for each puff. Initially, many cats resist the mask, so a gradual conditioning process over days to weeks is recommended before beginning actual medication delivery.

Training cats to accept the aerosol chamber typically involves gradual desensitization and positive reinforcement. The process often begins by simply allowing the cat to investigate the chamber and mask without any pressure, rewarding calm behavior with treats or praise. Over subsequent sessions, the mask is briefly touched to the face with rewards, then held in place for increasing durations. Once the cat tolerates the mask placement calmly, the sound of the inhaler actuation can be introduced, again with rewards. Finally, actual medication delivery begins. This training process may take one to three weeks but results in much less stressful treatments for both cat and owner over the long term. Rushing the training often leads to ongoing resistance.

The duration of beclomethasone therapy depends on the underlying condition and treatment response. Feline asthma is a chronic condition that typically requires ongoing management, so many cats continue inhaled corticosteroid therapy indefinitely. Regular veterinary evaluations assess disease control and determine if dose adjustments are needed. Some cats achieve excellent control and may have their frequency or dose reduced over time, while others require consistent therapy to maintain stability. Seasonal variations in symptoms may influence treatment intensity for some cats. The goal is to use the minimum effective dose that maintains good asthma control with minimal side effects.

Missed doses of inhaled beclomethasone should be administered as soon as remembered, then the regular schedule should be resumed. Since beclomethasone is a maintenance medication that works through gradual anti-inflammatory effects, missing occasional doses typically does not cause immediate symptom flares, though consistent use provides the best disease control. If multiple doses are missed due to travel, illness, or other circumstances, owners should contact their veterinarian for guidance, as some cats may need temporary increases in medication or additional treatments. Establishing a consistent daily routine for inhaler administration helps prevent missed doses.

Regular follow-up evaluation is essential during beclomethasone therapy to assess treatment effectiveness and monitor for any adverse effects. Veterinary visits may include physical examination, assessment of respiratory status, discussion of symptom frequency and severity, and sometimes chest radiographs to evaluate airway changes. Blood work may be periodically recommended to check for any systemic effects of corticosteroid therapy, though these are minimized with inhaled delivery. The veterinarian uses follow-up information to optimize the treatment plan, potentially adjusting beclomethasone doses or adding other medications as needed.

Inhaled beclomethasone has a favorable safety profile compared to systemic corticosteroids because the medication acts primarily in the airways with minimal absorption into the bloodstream. Most cats tolerate inhaled corticosteroid therapy well when administered correctly. However, potential side effects do exist, and pet owners should be aware of what to watch for during treatment. The local delivery of medication to the airways means that both local and, less commonly, systemic effects can occur. Understanding the potential adverse effects allows owners to monitor their cats appropriately and report concerns to their veterinarian.

Local side effects affecting the mouth and throat are among the most commonly observed adverse reactions to inhaled corticosteroids. Oral thrush, a fungal infection caused by Candida organisms, can develop due to the immunosuppressive effects of corticosteroids deposited in the oral cavity. Signs may include reluctance to eat, drooling, or visible white patches in the mouth. Upper respiratory symptoms including nasal irritation or discharge may occasionally occur. These local effects can often be minimized by using the aerosol chamber properly to maximize medication delivery to the lower airways and by wiping the cat's face after treatment. If oral thrush develops, antifungal treatment may be needed.

Systemic side effects from inhaled beclomethasone are less common and generally less severe than those associated with oral corticosteroids, but they can occur, particularly with higher doses or long-term use. Some systemic absorption of inhaled medication does occur, and cats receiving high doses may show mild increases in thirst and urination or changes in appetite. Weight gain is possible with long-term use. More significant systemic effects such as diabetes mellitus risk or substantial immune suppression are uncommon with properly dosed inhaled therapy but remain theoretical concerns, especially in cats with predisposing factors. Regular veterinary monitoring helps identify any emerging systemic effects.

Behavioral changes have been reported in some cats receiving corticosteroid therapy, though these are more commonly associated with systemic administration. Possible changes may include increased lethargy, changes in activity level, or alterations in social behavior. Since these changes can be subtle and develop gradually, pet owners should pay attention to their cat's overall demeanor and report significant changes. Distinguishing medication effects from changes related to the underlying respiratory condition or other factors can be challenging, and veterinary evaluation may be needed to determine the cause of behavioral changes.

Long-term use of inhaled corticosteroids requires ongoing awareness of potential cumulative effects. Adrenal suppression is theoretically possible with prolonged high-dose therapy, meaning the body's natural cortisol production may decrease. This is generally less concerning with inhaled than systemic steroids but should be considered if the cat requires sudden discontinuation or surgical procedures. Long-term airway effects and the potential for local immunosuppression to predispose to respiratory infections are additional considerations. Regular veterinary monitoring throughout therapy helps identify any emerging problems and allows for treatment adjustments to optimize the balance between disease control and medication safety.

Beclomethasone is contraindicated in cats with known hypersensitivity to beclomethasone or other corticosteroids. While true allergic reactions to corticosteroids are rare, cats that have experienced adverse reactions to any corticosteroid medication should have this history carefully evaluated before prescribing inhaled beclomethasone. Cross-reactivity between different corticosteroids is possible. Signs of hypersensitivity may include facial swelling, hives, worsening respiratory symptoms, or other allergic manifestations. Any history of corticosteroid reactions should be documented in the cat's medical record and communicated to all veterinary providers involved in the cat's care.

Active respiratory infections represent a relative contraindication or significant precaution for inhaled corticosteroid use. Corticosteroids have immunosuppressive effects that can impair the body's ability to fight infections. Cats with active bacterial, viral, or fungal respiratory infections may experience worsening of their infection if corticosteroids are administered. Treatment of the underlying infection should generally be completed or well underway before initiating or resuming inhaled corticosteroid therapy. In some cases, antibiotics or antifungal medications may be prescribed concurrently with inhaled steroids when both infection and inflammatory disease require treatment, but this requires careful veterinary judgment.

Certain systemic health conditions warrant careful consideration before prescribing inhaled beclomethasone. Diabetes mellitus may be affected by corticosteroid therapy, as these medications can raise blood glucose levels and potentially worsen diabetic control. While inhaled delivery minimizes systemic absorption, diabetic cats should be monitored more closely during beclomethasone therapy. Immunocompromised cats may be at increased risk of infections with corticosteroid use. Cats with systemic fungal infections generally should not receive corticosteroids until the infection is adequately controlled. The veterinarian weighs the benefits of respiratory disease control against potential risks in cats with these conditions.

Pregnancy, nursing, and pediatric use present additional considerations for inhaled beclomethasone. The safety of inhaled corticosteroids during feline pregnancy has not been thoroughly established, and potential effects on fetal development must be weighed against the risks of uncontrolled respiratory disease in the mother. Nursing queens present similar concerns due to potential transfer of medication to kittens through milk, though systemic absorption of inhaled beclomethasone is relatively low. Very young kittens may have difficulty tolerating the aerosol chamber and mask, and their developing systems may respond differently to corticosteroid exposure. Veterinary guidance is essential when considering inhaled corticosteroid therapy in these special populations.

Informing the veterinarian about all medications, supplements, and treatments a cat is receiving is essential before starting inhaled beclomethasone therapy. While inhaled corticosteroids have fewer systemic drug interactions than oral steroids due to their localized action, potential interactions still exist. The veterinarian needs complete information about the cat's medication regimen to ensure safe and effective therapy and to anticipate any potential interactions that might affect treatment outcomes or safety.

Concurrent use of systemic corticosteroids with inhaled beclomethasone requires careful consideration. Cats transitioning from oral prednisolone to inhaled therapy typically undergo a gradual tapering process, and the combined corticosteroid load during this transition must be monitored. Using both systemic and inhaled corticosteroids at full doses simultaneously increases the risk of corticosteroid side effects including adrenal suppression, immune suppression, and metabolic effects. Veterinarians carefully coordinate the transition to achieve adequate respiratory control while minimizing total steroid exposure. Once transitioned, most cats can be maintained on inhaled therapy alone.

Certain medications that affect immune function may have additive effects with inhaled corticosteroids. Other immunosuppressive drugs, including cyclosporine which is occasionally used in cats, combined with corticosteroids may further impair immune responses and increase infection risk. Cats receiving multiple immunosuppressive therapies require careful monitoring for signs of infection. Conversely, some medications may interfere with corticosteroid effects or require dose adjustments. The veterinarian considers all concurrent medications when developing treatment plans for cats receiving inhaled beclomethasone.

Bronchodilator medications are commonly used alongside inhaled corticosteroids for comprehensive asthma management, and this combination is generally safe and complementary. Inhaled beta-agonists like albuterol or oral bronchodilators like terbutaline and theophylline work through different mechanisms than corticosteroids, providing symptom relief while beclomethasone addresses underlying inflammation. When using both an inhaled bronchodilator and inhaled corticosteroid, some protocols recommend administering the bronchodilator first to open the airways, potentially improving corticosteroid deposition. However, specific administration sequences should follow veterinary guidance for the individual patient.

General precautions for inhaled beclomethasone emphasize proper administration technique, gradual introduction to the cat, and consistent use for optimal results. The aerosol chamber and mask must be used correctly to ensure adequate medication delivery to the airways rather than deposition in the mouth or throat. Pet owners should receive thorough training in administration technique and have the opportunity to demonstrate the process under veterinary supervision. The face mask must create a proper seal, and the cat should take sufficient breaths through the chamber after each inhaler actuation. Poor technique reduces effectiveness and may increase local side effects.

Breed-specific concerns for inhaled beclomethasone relate primarily to respiratory anatomy and predisposition to certain health conditions. Brachycephalic breeds such as Persians and Himalayans have shortened airways that may affect both the underlying respiratory condition and the delivery of inhaled medications. These cats may also have difficulty tolerating the face mask due to their facial conformation, and specially sized masks may be needed. Breeds predisposed to diabetes, such as Burmese cats, should be monitored more closely during corticosteroid therapy for any effects on glucose metabolism. Siamese and Oriental breeds, which have higher asthma rates, are frequent candidates for inhaled corticosteroid therapy but do not appear to have unusual sensitivities to these medications.

Proper handling of the metered-dose inhaler and aerosol chamber ensures consistent medication delivery. The inhaler should be shaken before each use to ensure proper mixing of medication and propellant. Priming the inhaler according to manufacturer instructions is important when new or after extended periods of non-use. The aerosol chamber should be kept clean and replaced periodically according to manufacturer recommendations, as medication can build up on internal surfaces and reduce the amount delivered to the cat. Using the chamber with an antistatic technique, such as washing with dish soap and allowing to air dry without rinsing, can improve medication delivery by reducing electrostatic attraction of particles to chamber walls.

Monitoring during beclomethasone therapy includes watching for both therapeutic response and potential adverse effects. Signs of good asthma control include reduced coughing frequency and severity, absence of wheezing, normal activity levels, and decreased need for rescue bronchodilator medications. Pet owners should track symptoms and medication use to share with the veterinarian at follow-up visits. Warning signs that may indicate inadequate control or adverse effects include persistent or worsening respiratory symptoms, development of oral lesions, excessive thirst or urination, or significant behavioral changes. Regular veterinary evaluation helps optimize treatment for each individual cat.

Special populations requiring additional consideration include geriatric cats, young kittens, and cats with multiple health conditions. Older cats may have concurrent conditions such as diabetes or chronic kidney disease that influence treatment decisions for respiratory disease. They may also have reduced ability to tolerate the stress of aerosol chamber training. Kittens require careful attention to mask sizing and may need modified training approaches. Cats with other chronic illnesses require individualized treatment plans that account for all their health issues. Immunocompromised cats should be monitored particularly closely for any signs of infection during corticosteroid therapy.

Proper storage of the beclomethasone metered-dose inhaler ensures the medication remains effective and delivers accurate doses throughout its use. The inhaler should be stored at room temperature, typically between 68 and 77 degrees Fahrenheit, as extremes of temperature can affect the propellant and medication delivery. The canister should not be exposed to temperatures above 120 degrees Fahrenheit or stored in direct sunlight, as this can cause pressure buildup. Freezing should also be avoided. Storage near heat sources such as stoves, radiators, or in vehicles during hot weather should be avoided. The protective cap should remain on the mouthpiece when the inhaler is not in use.

The metered-dose inhaler requires specific handling practices for optimal performance. Before each use, the canister should be shaken well to ensure proper mixing of medication and propellant. New inhalers should be primed by releasing several test sprays away from the face before first use, and priming may also be needed if the inhaler has not been used for several days. The inhaler should be held upright during actuation. Keeping track of the number of doses used ensures the inhaler is replaced before running empty, as the last doses may contain less medication even though propellant still sprays. Some inhalers have dose counters to assist with tracking.

The aerosol chamber requires separate care and maintenance to ensure effective medication delivery. The chamber should be cleaned regularly according to manufacturer instructions, typically by washing with mild dish soap and warm water. Importantly, the chamber should be allowed to air dry without rinsing or towel drying to allow a thin soap film to reduce static electricity, which can cause medication particles to stick to chamber walls instead of being inhaled. The face mask should be inspected regularly for cracks or damage that could affect the seal. Chambers should be replaced periodically as recommended by the manufacturer, typically every six to twelve months, as plastic can degrade and affect performance. The chamber and inhaler should be stored together in a clean, dry location accessible for daily use but away from curious pets.

Safe handling and disposal practices protect household members and the environment. Metered-dose inhalers are pressurized containers and should not be punctured or incinerated. Used or expired inhalers should be disposed of according to local pharmaceutical disposal guidelines or through veterinary take-back programs. The medication should be kept out of reach of children and other pets to prevent accidental exposure. While the medication doses are small, repeated accidental inhalation by children or other animals should be avoided. Pet owners should wash their hands after handling the inhaler and chamber.

Inhaled beclomethasone is generally effective across all cat breeds for managing respiratory inflammation when administered properly. There are no documented breed-specific sensitivities to beclomethasone itself, but certain breeds have predispositions to conditions that influence how therapy is approached or monitored. Understanding these breed-related factors helps veterinarians and pet owners optimize treatment for individual cats while maintaining awareness of potential concerns specific to certain breeds.

Breeds with increased prevalence of feline asthma are the most frequent candidates for inhaled corticosteroid therapy. Siamese and Oriental breeds appear to have higher rates of asthma compared to the general cat population, possibly due to genetic factors affecting airway reactivity. These breeds may require earlier and more aggressive treatment to maintain good respiratory control. Despite being more likely to receive inhaled beclomethasone, Siamese cats do not appear to have unusual responses to the medication itself. Owners of predisposed breeds should be educated about asthma signs and the importance of prompt treatment when symptoms develop.

Brachycephalic breeds including Persians, Himalayans, and Exotic Shorthairs present unique considerations for inhaled therapy. Their shortened facial structure can complicate aerosol chamber use, as standard face masks may not fit properly over their flat faces. Specially designed or sized masks may be needed to achieve an adequate seal for medication delivery. Additionally, brachycephalic cats may have complex respiratory conditions beyond simple asthma, including conformational issues that contribute to breathing difficulties. Thorough evaluation to characterize the respiratory condition is important before assuming inhaled corticosteroid therapy is the appropriate treatment. These breeds may also have more difficulty tolerating the stress of mask placement.

Breeds with predispositions to metabolic conditions require additional monitoring during corticosteroid therapy. Burmese cats have increased diabetes risk, and while inhaled beclomethasone has minimal systemic effects, monitoring for glucose metabolism changes is prudent in predisposed individuals. Similarly, cats of any breed with pre-existing diabetes should have their glucose control monitored more closely when receiving corticosteroids. Large breed cats may require attention to mask sizing for proper fit, while small cats benefit from accurate dose delivery that the aerosol chamber system provides. Age-related considerations apply across breeds, with geriatric cats potentially having concurrent conditions affecting treatment planning.

Several other inhaled corticosteroids are used in feline medicine as alternatives to beclomethasone. Fluticasone, available as Flovent, is the most commonly prescribed inhaled corticosteroid for cats and has the most veterinary experience supporting its use. Fluticasone is available in multiple strengths, allowing flexible dosing. Budesonide is another inhaled corticosteroid option that may be used in cats requiring maintenance anti-inflammatory therapy. The choice among inhaled corticosteroids often depends on veterinary preference, availability, cost considerations, and individual patient response. Cats that do not respond adequately to one inhaled corticosteroid may benefit from trying an alternative.

Bronchodilator medications are frequently used in combination with inhaled corticosteroids for comprehensive asthma management. Albuterol, administered via metered-dose inhaler through the aerosol chamber, serves as a rescue bronchodilator for acute symptoms. This combination approach mirrors human asthma treatment protocols. Oral bronchodilators such as terbutaline and theophylline may be used instead of or in addition to inhaled bronchodilators, depending on disease severity and patient factors. Injectable terbutaline may be prescribed for emergency home use in cats with severe asthma prone to acute attacks. The corticosteroid addresses underlying inflammation while bronchodilators provide symptom relief, and together they offer comprehensive disease management.

Systemic corticosteroids such as oral prednisolone represent an alternative approach for cats that cannot tolerate inhaled therapy or require more intensive treatment. While systemic steroids are effective for controlling airway inflammation, they carry greater risk of side effects including increased thirst and urination, weight gain, diabetes, and immune suppression. Many cats begin asthma treatment with oral prednisolone and transition to inhaled corticosteroids once stable, reducing long-term systemic steroid exposure. In severe cases, both systemic and inhaled corticosteroids may be used together temporarily, with careful monitoring and the goal of eventually transitioning to inhaled therapy alone. The optimal approach depends on disease severity, patient factors, and treatment response.